Browse studies

Find your next paid study

177 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1 Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of Gepotidacin in Healthy Lactating Women

This study aims to evaluate the pharmacokinetic of gepotidacin in fed healthy lactating women.

Urinary Tract Infections

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07645235

Phase 2

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study…

Epstein-Barr Virus InfectionsLymphomaLymphoproliferative Disorder+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03258567

Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)

The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) …

HIV Infections

Estimated

~$10 – $1,125

Gilead SciencesNCT07473778

Phase 1

Geroprotective Precision Medicine Strategies in PWH That Use Alcohol

People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, cr…

HIV InfectionsAlcohol DrinkingAging+1 more

Estimated

~$10 – $6,250

Louisiana State University Health Sciences Center in New OrleansNCT07462767

Phase 3

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce…

HypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic Leukemia+2 more

Estimated

~$10 – $8,750

Grifols Therapeutics LLCNCT05645107

Natural History, Genetics, Phenotype, and Treatment of Mycobacterial Infections

This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in th…

Mycobacterium Infections

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00018044

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Background: Staphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these inf…

Staphylococcal Infections

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT06479837

Phase 1

A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination …

Respiratory Syncytial Virus Infections+Metapneumovirus

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07628049

Observational

Enhanced Telemedicine in Primary Care for ARTIs (Tele-PARTI) Study

Young children often receive antibiotics for pediatric acute respiratory tract infections (ARTIs) - common childhood diagnoses like ear infections, strep throa…

Acute Respiratory Tract InfectionEar InfectionThroat Infection+2 more

Estimated

~$10 – $6,250

University of PittsburghNCT07845526

Phase 2

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease

The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk…

Respiratory Syncytial Virus Infections

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients With Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment With B-cell Depletion Therapy ("PROTECT")

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Pa…

HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions+1 more

Estimated

~$10 – $8,750

OctapharmaNCT07220915

Phase 3

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in parti…

Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection Recurrence+7 more

Estimated

~$10 – $8,750

Vedanta Biosciences, Inc.NCT06237452